Trial results for a Phase 3 study evaluating tiragolumab plus atezolizumab for non-small cell lung cancer (NSCLC) were posted on ClinicalTrials.gov on 2026-06-10. The study was terminated, with adverse events reported in 26 participants in the control arm and 21 participants in the experimental arm.
Background
The study investigated atezolizumab (Tecentriq), in combination with tiragolumab, for participants with non-small cell lung cancer (NSCLC). This combination therapy was explored in patients who had undergone complete surgical resection of their NSCLC and subsequently received adjuvant platinum-based chemotherapy. The goal was to assess the potential benefits of adding tiragolumab to atezolizumab in this specific post-surgical setting.
Trial design
The terminated Phase 3 study (NCT06267001) enrolled 56 participants with non-small cell lung cancer (NSCLC). Its primary purpose was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab. This comparison was administered to participants with completely resected NSCLC who had also received adjuvant platinum-based chemotherapy, aiming to understand the potential impact of the combination therapy in preventing disease recurrence or improving outcomes in this high-risk population.
Key results
The trial reported adverse event data:
- In the Atezolizumab ± Placebo group, 26 participants experienced adverse events.
- In the Tiragolumab + Atezolizumab group, 21 participants experienced adverse events.
What this means
The termination of this Phase 3 study means that no efficacy data comparing tiragolumab plus atezolizumab to placebo plus atezolizumab for non-small cell lung cancer was made available. Consequently, the trial's ability to demonstrate any benefit of the combination therapy in this patient population remains unaddressed. The posted results are limited to adverse event counts, showing 26 participants in the control arm and 21 participants in the experimental arm experienced adverse events. Without further details on the specific reasons for termination, such as safety concerns or lack of efficacy, or any statistical analysis of these safety outcomes, the clinical implications of these specific adverse event counts are not clear. Clinicians and researchers will need to await further information to understand the full context of this trial's termination.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06267001, titled "A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy", were posted on 2026-06-10 on clinicaltrials.gov.